Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation

Cristina E Tognon1, Cameron D Mackereth, Aruna M Somasiri

  • 1Department of Pathology, BC Research Institute for Children's and Women's Health, 950 West 28th St., Vancouver, British Columbia V5Z 4H4, Canada.

Insights

ETV6-NTRK3 (EN) cancer-causing activity relies on protein polymerization, not just dimerization. Disrupting EN polymerization prevents its oncogenic function, suggesting polymerization is key for ETV6-PTK fusion proteins.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Chromosomal translocations involving the ETV6 (TEL) gene create oncogenic fusion proteins.
  • ETV6-NTRK3 (EN) is a unique chimeric oncoprotein found in diverse cancers, fusing the ETV6 SAM domain with the NTRK3 protein tyrosine kinase (PTK).
  • Previous hypotheses suggested SAM-domain-mediated dimerization activates EN's PTK activity.

Purpose of the Study:

  • To investigate the role of ETV6 SAM domain interactions in ETV6-NTRK3 (EN) oncogenic activity.
  • To determine if protein polymerization, rather than dimerization, is critical for EN's transformation potential.
  • To explore the mechanism of EN-mediated cellular transformation.

Main Methods:

  • Utilized an inducible FK506 binding protein (FKBP) dimerization system to replace the EN SAM domain.
  • Created mutations in the EN SAM binding interfaces to disrupt self-association and polymerization.
  • Assessed NIH 3T3 cell transformation, PTK activation, and protein structure (monomers vs. polymers) using microscopy.

Main Results:

  • FKBP-NTRK3 chimeras failed to transform cells despite preserved PTK activation, indicating dimerization alone is insufficient.
  • Mutations disrupting EN SAM domain self-association abolished polymerization, PTK activation, and cell transformation.
  • EN formed polymeric structures in cells, while mutant proteins remained monomers.
  • Coexpression of isolated SAM domains exerted a dominant negative effect on EN transformation.

Conclusions:

  • Higher-order polymerization of the ETV6 SAM domain is essential for ETV6-NTRK3 (EN) transformation activity.
  • This finding challenges the dimerization-based activation model and highlights polymerization as a critical mechanism for EN and potentially other ETV6-PTK fusion proteins.
  • The study provides new insights into the molecular mechanisms driving oncogenesis by ETV6 fusion proteins.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...